AstraZeneca, BMS Provide Grant for Diabetes Research Initiative
PTSM: Pharmaceutical Technology Sourcing and Management
AstraZeneca and Bristol-Myers Squibb Diabetes Alliance provides a $5 million grant to the American Diabetes Association.
AstraZeneca and Bristol-Myers Squibb reported that the companies’ US Diabetes Alliance is providing a three-year grant to the American Diabetes Association’s Pathway to Stop Diabetes program. The research initiative provides resources and support for a new generation of diabetes researchers and is designed to generate discoveries through collaboration and radical thinking.
The 2013 Pathway Awards will provide $1.6 million in support for five to seven years for the selected investigators and will fund research relevant to any diabetes type, diabetes-related disease state, or diabetes complication. Nominations included a range of disciplines, including medicine, biology, chemistry, engineering, physics, and mathematics.
Source: Bristol-Myers Squibb
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
